News archive

April 3, 2024
Bergen, Norway, 3rd April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully reached the target for pilot production of the Sencell sensor. Reports show a breakthrough, and this will pave the way for the automated production by end of Q2 as scheduled. Reference […]
Read more
March 21, 2024
Bergen, Norway, March 21st, 2024: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has notified that they will grant for a new patent to Lifecare. Reference is made to stock exchange notification November 8th, 2023, that EPO intended […]
Read more
March 6, 2024
Today starts the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2024) in Firenze. Lifecare will be represented at the conference and have been accepted to present three poster presentations. ATTD is a leading international diabetes technology forum where clinicians, diabetes care providers, researchers, industries, start-up, investors, reimbursement authorities, regulators and people with […]
Read more
March 5, 2024
Bergen, Norway, 5 March 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a cleanroom. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th, 2023 and later […]
Read more
February 27, 2024
Bergen, Norway, February 27th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q4 financial report and operational update. Lifecare holds steady a course towards the upcoming automated pilot production. The first three quarters of 2023, Lifecare reported on huge achievements both […]
Read more
February 21, 2024
Bergen, Norway, February 21st, 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces today that the Board of Directors has decided to prepare for submitting application for listing of Lifecare’s shares at the main list of Oslo Stock Exchange (OSE), transferring from the current listing […]
Read more
February 14, 2024
Bergen, Norway, 14 February 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully finished the first and important step of software implementation and coding for the upcoming automated pilot production. In addition to this Lifecare has received confirmation of delivery of essential equipment. Reference […]
Read more
February 2, 2024
Bergen, Norway, 1 February 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has appointed Torsten Ernst as Production Manager effective 1 March 2024. This appointment will strengthen our production team. Ernst is an industry specialist with a track record in making new solutions manufacturable, and […]
Read more
January 3, 2024
The technology development and company progress were fantastic in 2023. We expect nothing less in 2024, in our mission to make life easier for patients and pets with diabetes.    Photo: Joacim Holter, CEO at Lifecare One year ago, we communicated Lifecare’s focus in 2023 to continue the core product development, achieve ISO 9001 and […]
Read more
December 13, 2023
Bergen, Norway, December 13th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that yet an additional preparational step for the Company’s automated production has been met as Lifecare has placed the purchase order for a BioScaffolder (“BS 3.3) and a customized Nano-Plotter […]
Read more